netFormulary NHS
Birmingham, Sandwell, Solihull and environs APC Formulary
Maintained by Midlands and Lancashire Commissioning Support Unit
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Section
Notes:

For the most up to date list of agents funded by the Cancer Drugs Fund, please see Cancer Drug Fund list

Numbers in brackets indicate counts of (Formulary items, Non Formulary items)
08.01 Cytotoxic drugs (0,1)
Side-effects of cytotoxic drugs (0,1)
Drugs for cytotoxic-induced side-effects (0,7)
08.01.01 Alkylating drugs (9,0)
08.01.02 Anthracyclines and other cytotoxic antibiotics (2,0)
08.01.03 Antimetabolites (11,0)
08.01.04 Vinca alkaloids and etoposide (1,2)
08.01.05 Other antineoplastic drugs (29,2)
Amsacrine (0,1)
Arsenic trioxide (1,0)
Bevacizumab (1,0)
Bexarotene (1,0)
Bortezomib (1,0)
Brentuximab vedotin (1,0)
Cetuximab (1,0)
Crisantaspase (1,0)
Dacarbazine and Temozolomide (1,1)
Erlotinib (1,0)
Hydroxycarbamide (1,0)
Imatinab (0,0)
Ipilimumab (1,0)
Mitotane (1,0)
Panitumumab (1,0)
Pentostatin (0,1)
Platinum compounds (1,2)
Porfimer sodium and temoporfin (0,2)
Procarbazine (1,0)
Protein kinase inhibitors (18,2)
Taxanes (4,0)
Topoisomerase I inhibitors (1,1)
Trabectedin (0,1)
Trastuzumab (3,0)
Tretinoin (0,1)
Vismodegib (0,1)
08.02 Drugs affecting the immune response (0,1)
Immunosuppressant therapy (0,0)
08.02.01 Antiproliferative immunosuppressants (2,1)
08.02.02 Corticosteroids and other immunosuppressants (4,2)
08.02.03 Anti-lymphocyte monoclonal antibodies (11,0)
08.02.04 Other immunomodulating drugs (3,4)
Interferon Alfa (2,0)
Interferon beta (0,5)
Interferon gamma (0,0)
Aldesleukin (0,1)
BCG bladder instillation (0,0)
Canakinumab (0,0)
Dimethyl fumarate (1,0)
Fingolimod (1,0)
Glatiramer acetate (0,1)
Histamine (0,0)
Lenalidomide, pomalidomide, and thalidomide (2,0)
Mifamurtide (1,0)
Natalizumab (1,0)
Teriflunomide (1,0)
08.03 Sex hormones and hormone antagonists in malignant disease (0,0)
08.03.01 Oestrogens (1,1)
08.03.02 Progestogens (3,0)
08.03.03 Androgens (0,0)
08.03.04 Hormone antagonists (0,0)
08.03.04.01 Breast cancer (4,3)
08.03.04.02 Prostate cancer and gonadorelin analogues (0,0)
Gonadorelin analogues (1,1)
Anti-androgens (11,1)
Gonadotrophin-releasing hormone antagonists (0,0)
08.03.04.03 Somatostatin analogues (5,0)
netFormulary